Ralf Agger

Ralf Agger is an Associate Professor affiliated with the Department of Medicine and Health Technology under the Faculty of Health Sciences at Aalborg University. His research focuses on immunology, dendritic cell biology, vaccine development, and cancer immunotherapy, with expertise in flow cytometry and electroporation techniques.

His recent work explores dendritic cell-targeted cancer vaccines, cholesterol-binding motifs in STING signaling, and combination immunotherapy approaches for pancreatic cancer metastasis. Key subfields include tumor immunology, antigen presentation, and nucleotide-based vaccine technologies.

Agger has co-authored 104 publications over his career, with active research in 2024 involving clinical trials (e.g., EPIC-1 study on electroporation-potentiated immunotherapy) and high-impact articles in journals like Nature Communications and Vaccine.